IL161248A0 - USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER - Google Patents

USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Info

Publication number
IL161248A0
IL161248A0 IL16124802A IL16124802A IL161248A0 IL 161248 A0 IL161248 A0 IL 161248A0 IL 16124802 A IL16124802 A IL 16124802A IL 16124802 A IL16124802 A IL 16124802A IL 161248 A0 IL161248 A0 IL 161248A0
Authority
IL
Israel
Prior art keywords
estra
benzodioxol
dien
propynyl
hydroxy
Prior art date
Application number
IL16124802A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of IL161248A0 publication Critical patent/IL161248A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16124802A 2001-10-26 2002-10-21 USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IL161248A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204072 2001-10-26
PCT/EP2002/011732 WO2003037354A1 (en) 2001-10-26 2002-10-21 USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Publications (1)

Publication Number Publication Date
IL161248A0 true IL161248A0 (en) 2004-09-27

Family

ID=8181136

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16124802A IL161248A0 (en) 2001-10-26 2002-10-21 USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
IL161248A IL161248A (en) 2001-10-26 2004-04-01 Use of (11,17)-11-(1, 3 - benzodioxol-5-yl)-17- hydroxy-17-(1-propynyl)-estra- 4, 9 - dien-3-one for the preparation of a medicament for the treatment of major depressive disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161248A IL161248A (en) 2001-10-26 2004-04-01 Use of (11,17)-11-(1, 3 - benzodioxol-5-yl)-17- hydroxy-17-(1-propynyl)-estra- 4, 9 - dien-3-one for the preparation of a medicament for the treatment of major depressive disorder

Country Status (26)

Country Link
US (1) US20040266863A1 (https=)
EP (2) EP1652526B1 (https=)
JP (1) JP4647909B2 (https=)
KR (1) KR20050038580A (https=)
CN (1) CN100531738C (https=)
AT (2) ATE317700T1 (https=)
AU (1) AU2002348996B2 (https=)
BR (1) BR0213466A (https=)
CA (1) CA2463446C (https=)
CY (1) CY1110173T1 (https=)
DE (2) DE60230936D1 (https=)
DK (1) DK1652526T3 (https=)
EC (1) ECSP045080A (https=)
ES (1) ES2319563T3 (https=)
HR (1) HRP20040370B1 (https=)
HU (1) HUP0500070A3 (https=)
IL (2) IL161248A0 (https=)
IS (1) IS2702B (https=)
MX (1) MXPA04003781A (https=)
NO (1) NO332978B1 (https=)
NZ (1) NZ532429A (https=)
PL (1) PL206687B1 (https=)
PT (1) PT1652526E (https=)
RU (1) RU2302245C2 (https=)
WO (1) WO2003037354A1 (https=)
ZA (1) ZA200403088B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス, インコーポレイテッド Il−2を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターiiアンタゴニストの使用
EP2671086B1 (en) * 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
US20120263660A1 (en) * 2011-04-18 2012-10-18 Pop Test Cortisol Llc Hair Loss Treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
DE4447401A1 (de) * 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
CN1820756A (zh) * 2001-03-23 2006-08-23 科塞普特治疗公司 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
DE60238671D1 (de) * 2001-05-04 2011-02-03 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
IL160649A0 (en) * 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome

Also Published As

Publication number Publication date
CA2463446C (en) 2010-02-23
EP1441739B1 (en) 2006-02-15
IL161248A (en) 2010-12-30
NO332978B1 (no) 2013-02-11
EP1652526A2 (en) 2006-05-03
US20040266863A1 (en) 2004-12-30
WO2003037354A1 (en) 2003-05-08
EP1652526A3 (en) 2006-08-02
DE60230936D1 (de) 2009-03-05
HUP0500070A2 (hu) 2005-04-28
ECSP045080A (es) 2004-06-28
PT1652526E (pt) 2009-02-06
ZA200403088B (en) 2005-01-24
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
CN100531738C (zh) 2009-08-26
BR0213466A (pt) 2004-11-09
IS7204A (is) 2004-03-31
ATE420649T1 (de) 2009-01-15
CA2463446A1 (en) 2003-05-08
CY1110173T1 (el) 2015-01-14
JP2005521637A (ja) 2005-07-21
HRP20040370A2 (en) 2004-08-31
EP1652526B1 (en) 2009-01-14
KR20050038580A (ko) 2005-04-27
HUP0500070A3 (en) 2012-09-28
PL206687B1 (pl) 2010-09-30
HRP20040370B1 (hr) 2012-09-30
CN1582153A (zh) 2005-02-16
JP4647909B2 (ja) 2011-03-09
NZ532429A (en) 2004-10-29
ATE317700T1 (de) 2006-03-15
IS2702B (is) 2010-11-15
DK1652526T3 (da) 2009-05-18
ES2319563T3 (es) 2009-05-08
HK1087357A1 (en) 2006-10-13
EP1441739A1 (en) 2004-08-04
PL369261A1 (en) 2005-04-18
AU2002348996B2 (en) 2008-06-05
DE60209248D1 (de) 2006-04-20
RU2004116082A (ru) 2005-05-10
MXPA04003781A (es) 2004-07-30

Similar Documents

Publication Publication Date Title
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
UA83620C2 (ru) Замещенные бензоксазолы и их аналоги как эстрогенные агенты
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
MXPA04005784A (es) 2-fenilbenzofuranos sustituidos como agentes estrogenitos.
SG153645A1 (en) Hormone replacement therapy
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
IL159714A (en) Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac
HUP0402028A3 (en) Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof
IL133632A (en) Use of a specific 5ht2 receptor antagonist for the preparation of pharmaceutical compositions useful in the treatment of the sleep apnea syndrome
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
WO2002074315A8 (de) Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
HUP0200253A3 (en) Pharmaceutical compositions for combination therapy
HK1068097A (en) Use of (11beta, 17beta)-11- (1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one in the treatment of major depressive disorder
IL157272A0 (en) Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
NO20022712L (no) Umettede 14,15-syklopropanandrostaner, fremgangsmåte for deres fremstilling, og farmasöytiske preparater som inneholderdisse forbindelsene
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia
EP1857110A3 (en) Hormone replacement therapy
BR0304292A (pt) Preparado de combinação de estrogênio-gestagênio e uso